DNTH · Dianthus Therapeutics, Inc. /DE/ · Congressional Trades
$78.75
+4.21 (+5.65%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the "issuance date") As of the issuance date, the Company expects that its existing cash, cash equivalents and investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date.”View the 10-Q filed Aug 4, 2026
Market Cap
$4.40B
Shares
55.93M
Volume · Oct 20
1.87M
Avg daily vol (3M)
822.38K
Transactions in this listed security by members of the U.S. Congress, disclosed under the STOCK Act. Lawmakers must report trades within 45 days, so the filing date can lag the trade itself.
No Congressional Trades
No congressional trading data is available for this listed security yet.
Key facts
CIK
1690585
CUSIP
252828108
13F (30d)
16 filings
16 filers
Visit website
Investor relations